About Tumor necrosis factor receptor superfamily member 10C
Tumor necrosis factor receptor superfamily member 10C (TNFRSF10C) is a protein
from Homo sapiens identified by UniProt accession
O14798, 259 residues long.
MolForge cross-references it against 0 known binders and
137 disease associations.
Target properties
| Protein name | Tumor necrosis factor receptor superfamily member 10C |
|---|
| UniProt accession | O14798 |
|---|
| Gene | TNFRSF10C |
|---|
| Organism | Homo sapiens |
|---|
| Length | 259 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (137)
Diseases linked to this target (Open Targets).
- leukocyte count · score 0.47
- neutrophil count · score 0.44
- eosinophil count · score 0.43
- basophil count · score 0.42
- myeloid white cell count · score 0.38
- eosinophil percentage of leukocytes · score 0.38
- mean corpuscular hemoglobin concentration · score 0.37
- monocyte percentage of leukocytes · score 0.33
- basophil percentage of leukocytes · score 0.32
- sum of basophil and neutrophil counts · score 0.28
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O14798-F1 | alphafold | PREDICTED | 71.61 | — |
Amino-acid sequence (259 residues)
MARIPKTLKF VVVIVAVLLP VLAYSATTAR QEEVPQQTVA PQQQRHSFKG EECPAGSHRS EHTGACNPCT EGVDYTNASN NEPSCFPCTV CKSDQKHKSS CTMTRDTVCQ CKEGTFRNEN SPEMCRKCSR CPSGEVQVSN CTSWDDIQCV EEFGANATVE TPAAEETMNT SPGTPAPAAE ETMNTSPGTP APAAEETMTT SPGTPAPAAE ETMTTSPGTP APAAEETMIT SPGTPASSHY LSCTIVGIIV LIVLLIVFV
Explore Tumor necrosis factor receptor superfamily member 10C with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets